This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Clinical Insider
search
Clinical Insider

QPS sells neuropharma unit and expands Missouri lab

Posted by on 05 December 2023
Share this article

QPS Holdings has sold its neuropharmacology business to Danish preclinical contractor, Scantox and expanded its clinical lab in Springfield, Missouri.

The sale of the neuropharmacology unit – financial terms of which were not disclosed – Scantox will gain QPS’ 2,700 meter squared facility in Grambach, Austria. QPS will retain its European clinical division, which includes operations in Austria, Czechia and Croatia.

The combined company will have more than 300 employees across six sites and will offer a range of services, from lead optimization, neuropharmacology research, regulatory toxicology and CMC/analysis.

According to QPS’ the neuropharmacology unit will continue to serve current clients as part of the Scantox organization.

QPS CEO, Ben Chien, framed the divestiture as part of a wider growth plan, explaining “the sale of QPS Neuropharmacology is a natural transition in the development of QPS as a full-service, global CRO focused on preclinical, bioanalysis and clinical research operational services.”

In a separate announcement, QPS said it has expanded its clinical services operations in Springfield, Missouri. The expanded facility includes a clinical laboratory, an updated self-contained pharmacy, and a dedicated space to build and ship clinical trial kits.

The Springfield campus now houses five independent clinics with over 240 Phase I clinical trial beds, multiple laboratories, a 2,500 square-foot negative pressure room, a pharmacy with a clean room, and a new Screening and Recruitment Center.

Brendon Bourg, QPS Missouri’s VP of early phase Clinical and head of administration said, “Adding this new safety lab to our local clinical trial facility means that our physicians can receive laboratory results in real-time, adding an additional level of safety for participants.”

Over the next few years, Bourg expects the new facilities to grow from providing services for clinical trials and begin providing central laboratory, pharmacy, and clinical trial kit-building services for multi-site clinical research projects.

DepositPhotos/thaneeh.gmail.com

Share this article

Sign up for Clinical Insider email updates

keyboard_arrow_down